Syndax Pharmaceuticals 10K 2020 Annual report | SNDX Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AbbVie, absenteeism, Aid, anesthesiologist, Attending, axatilimab, belief, Biden, bifurcated, bifurcation, Bio, biostatistic, carryback, caution, Center, cGVHDa, circumstance, cleaning, closure, constitutionality, COVID, Daphne, deprioritize, deprioritized, distancing, doctor, economy, embedded, entosplentinib, Exposition, Eytan, FedEx, forfeited, formation, formatted, fundamental, geopolitical, Hedging, HHS, hospital, Incyte, Inline, Island, JAK, judgement, Kadmon, Kettering, Kura, Lee, magnitude, Medicine, Memorial, methyl, multiorgan, NaN, nationwide, NIH, Northern, pandemic, path, perfect, postal, pronounced, recession, reconsider, remote, remotely, reopen, reprioritization, residence, Rhode, routinely, RSU, score, sequester, shelter, shifting, SIP, situation, Sloan, slowdown, spread, Stein, SYK, tie, today, transferase, truthful, unnecessary, verification, virtual, waived, whichwould, wild, workforce, worsening, xenograft

Removed: abemaciclib, absence, adhere, administered, Afinitor, alpelisib, antidilution, appointed, arm, ASU, atezolizumab, attributed, bavencio, bladder, BRAF, carcinoma, carry, CDK, circulating, classification, collaborated, colon, colorectal, combining, complementary, concentration, confidentially, confirm, conventional, dabrafenib, damage, Darmstadt, disposition, Dohme, dropping, DSMC, durvalumab, dying, dynamic, eliminate, emergence, ENCORE, endocrine, ensuring, ER, estrogen, evident, exploratory, expression, Faslodex, faster, fatigue, feedback, field, gastrointestinal, Genentech, Germany, GmbH, goal, halted, hematologic, hired, hormonal, Ibrance, immunologic, improve, improved, ipilmumab, Keytruda, KGaA, kinase, Kisqali, leaving, logistical, mammalian, managing, matching, median, Mekinist, melanoma, men, Merck, metastasized, metastatic, microsatellite, mode, modulation, monocyte, MSD, multicenter, nivolumab, NSCLC, observe, occurring, Opdivo, ovarian, overcome, overlapping, palbociclib, pancreatic, pembrolizumab, people, peripheral, Pfizer, PFS, pharmacologic, pharmacology, procuring, progressed, progression, prolong, proper, proportion, prospective, prostate, qualification, radiation, Raf, rapamycin, rationale, reach, reclassification, reclassified, regimen, reliance, relieve, remained, repealing, responding, responsive, retrospective, ribociclib, Richard, risen, Roche, room, sanctioned, Sharp, Shea, shortage, shorten, stable, statistician, stimulation, stopped, stricter, suited, supplying, Tafinlar, tecentriq, TNBC, toxic, trametinib, Treasurer, unexpectedly, unreasonably, unreliable, unresectable, unsafe, utilize, validation, vemurafenib, Verzenio, withdrawing, women, Yervoy, Zelboraf

Syndax Pharmaceuticals (SNDX) 10-K2020 FY Annual report

Content analysis